Approval of the third pan-HDAC inhibitor, belinostat was based on a multi-center, single arm BELIEF trial of 120 evaluable patients with PTCL that was refractory or had relapsed after prior treatment [54]. This evidence concerns the gene HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma.